Novartis reports positive data from COPD drug trial

Novartis has reported clinical data that demonstrates the safety and efficacy benefits provided by its chronic obstructive pulmonary disease (COPD) drug NVA237.

Results from the pivotal phase III GLOW2 trial showed that the glycopyrronium bromide therapy was superior to placebo in improving lung function, symptom relief and quality of life, while also reducing exacerbations over a one-year period.

A rapid onset of action was observed at first dose, followed by sustained 24-hour bronchodilation, while it was also shown to be well tolerated over 52 weeks.

This data will support Novartis' efforts to seek European regulatory approval for NVA237, which will be sold under the proposed brand name Seebri Breezhaler.

Tim Wright, head of development at Novartis Pharmaceuticals, said: "The GLOW2 results affirm the potential for once-daily NVA237 to help patients manage their COPD symptoms and improve their quality of life."

Earlier this month, the company reported positive clinical trial data on Lucentis, its treatment for wet age-related macular degeneration and diabetic macular oedema.